Author:
Kumar Naveen,Barua Sanjay,Kumar Ram,Khandelwal Nitin,Kumar Amit,Verma Assim,Singh Lokender,Godara Bhagraj,Chander Yogesh,Riyesh Thachamvally,Sharma Deepak Kumar,Pathak Anubha,Kumar Sanjay,Dedar Ramesh Kumar,Mehta Vishal,Gaur Mitesh,Bhardwaj Bhupendra,Vyas Vithilesh,Chaudhary Sarjeet,Yadav Vijaypal,Bhati Adrish,Kaul Rakesh,Bashir Arif,Andrabi Anjum,Yousuf Raja Wasim,Koul Abhimanyu,Kachhawa Subhash,Gurav Amol,Gautam Siddharth,Tiwari Hari Audh,Gupta Madhurendu K.,Kumar Rajender,Misri Jyoti,Kumar Ashok,Mohanty Ashok Kumar,Nandi Sukdeb,Singh Karam Pal,Pal Yash,Dutt Triveni,Tripathi Bhupendra N.
Abstract
ABSTRACTLumpy skin disease (LSD) was reported for the first time in India in 2019 and since then, it has become endemic. Since a homologous (LSD-virus based) vaccine was not available in the country, goatpox virus (GPV)-based heterologous vaccine was authorized for mass immunization against LSD in cattle. This study describes the evaluation of safety, immunogenicity and efficacy of a new live-attenuated LSD vaccine developed using an Indian field strain (LSDV/India/2019/Ranchi). The virus was attenuated by continuous passage (P=50) in Vero cells. The vaccine (50thLSDV passage in Vero cells, named as Lumpi-ProVacInd) did not induce any local or systemic reaction upon its experimental inoculation in calves (n=10). At day 30 post-vaccination (pv), the vaccinated animals were shown to develop antibody- and cell-mediated immune response and exhibited complete protection upon virulent LSDV challenge. We observed a minimum Neethling response (0.018% animals; 5 out of 26940 animals) of the vaccine in field trials among 26940 animals. There was no significant reduction in the milk yield in lactating animals (n=10108), besides there was no abortion or any other reproductive disorder in the pregnant animals (n=2889). Sero-conversion was observed in 85.18% animals in the field by day 30 pv.
Publisher
Cold Spring Harbor Laboratory